Lv2
120 积分 2023-05-18 加入
A Multicenter Phase II Study of Locoregional Gemcitabine Combined with Surufatinib and Camrelizumab in FGFR2 Non-Altered Intrahepatic Cholangiocarcinoma
4天前
已关闭
EV344/#770 Surufatinib combined with toripalimab for the treatment of recurrent ovarian clear cell carcinoma: a prospective single center, single-arm phase II clinical trial
1个月前
已关闭
Gastrohepatic Fistula Secondary to Metastatic Colon Cancer as a Rare Etiology of Upper Gastrointestinal Bleed
3个月前
已完结
766P Efficacy and safety of concurrent bevacizumab in combination with standard radiotherapy and temozolomide followed by bevacizumab in combination with temozolomide and surufatinib in glioblastoma: A phase II clinical trial
3个月前
已关闭
81P Stereotactic body radiation therapy followed by fruquintinib in combination with immunotherapy as third- and later-line treatment in metastatic colorectal cancer
3个月前
已关闭
Le fruquintinib dans le cancer colorectal métastatique en échec des traitements standards
5个月前
已关闭
EP.12A.38 Durable Response to Savolitinib in Advanced EGFR-WT NSCLC with MET Amplification: Case Series
5个月前
已关闭
Savolitinib in NSCLC: progress in the MET exon 14 journey
6个月前
已完结
Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma
10个月前
已完结
Efficacy and Safety of Surufatinib for Recurrent or Metastatic Malignant Salivary Gland Tumors: An Open-Label, Single-Arm, Phase II Study
1年前
已完结
皖公网安备34019202002308
